Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: Recovery Effects After Semaglutide Termination

Plain-language guide to NCT07294950: phase 3 randomized trial of Semaglutide, low blood pressure and orthostatic hypotension, 98 participants. Who took part, design and what was measured.

Key Facts

Registry ID: NCT07294950
Phase: phase 3
Status: recruiting participants
Start: 2026-02-01
Completion (planned or actual): 2028-09
Participants: 98 (estimated)
Design: randomized, open label (everyone knows who gets what), treatment
Conditions studied: Obesity (Disorder); Weight Change; Blood Pressure Monitoring; Appetite Regulation
Results posted: not yet

What This Study Did, in Plain Language

What Was Tested

This registered phase 3 trial tested Semaglutide for low blood pressure and orthostatic hypotension.

Semaglutide is a medication from the class of drugs called glucagon-like peptide-1 agonists that promote weight loss.

It had two arms (groups): one (experimental) and Cessation of semaglutide (active comparator).

Participants will discontinue treatment at once at week 16.

The registry classes the interventions as drug.

Who Took Part

The registry lists 98 planned participants were the target.

It was open to people of any sex aged from 18 years up to 75 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Age 18 - 75 years inclusive. Ability to read and understand English.

The full record lists 5 inclusion and 12 exclusion criteria; among the exclusions: currently pregnant or lactating; previously diagnosed type 2 diabetes; previous surgical treatment for weight loss such as gastric bypass or gastric band.

How the Study Was Run

It was run as a randomized, parallel-group and open-label study.

Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The Semaglutide group and the comparison group ran side by side rather than switching.

Being open-label, the Semaglutide study did not mask who received what.

It started in 2026-02-01 with completion listed for 2028-09.

It ran at 1 site in Canada.

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: Differences in changes in body weight between each study group (time frame: 32 weeks).

It also tracked 2 secondary outcomes, for example Differences in 24-h systolic BP levels between each study group and Differences in fasting ghrelin between each study group.

What This Means in Plain Language

Put simply, this is a phase 3, randomized trial of Semaglutide in 98 people with low blood pressure and orthostatic hypotension.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, Low blood pressure and orthostatic hypotension research.

Our Notes on the Compound

Semaglutide: The active ingredient in several prescription GLP-1 receptor agonist medicines (Ozempic, Wegovy, oral tablets).

Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.